CorMedix Inc. filings document the regulatory record of a Nasdaq-listed biopharmaceutical company commercializing DefenCath and a broader portfolio of institutional-care specialty pharmaceuticals. Form 8-K reports cover operating results, financial condition, corporate presentations, material-event disclosures, clinical or regulatory updates and business developments following the completed Melinta Therapeutics acquisition.
Proxy statements describe shareholder voting matters, board and governance practices, equity incentive plan proposals, certificate of incorporation matters and preferred-stock voting provisions. Acquisition-related amendments include financial statements of the acquired business and pro forma financial information, while the company’s securities disclosures identify CRMD common stock listed on the Nasdaq Global Market.
CorMedix Inc.'s Chief Operating Officer, Elizabeth Hurlburt, reported a Form 4 insider transaction involving company common stock. On 01/12/2026, a transaction coded "F" was reported for 5,794 shares of common stock at a price of $7.15 per share. Following this transaction, she directly beneficially owned 160,301 shares of CorMedix common stock. The filing notes that the transaction is being reported late due to an inadvertent administrative error.
CorMedix Inc. Chief Executive Officer Joseph Todisco, who also serves as a director, reported equity award-related transactions in the company’s common stock. On 01/16/2026, he exercised a stock option for 29,585 shares of common stock at an exercise price of $3.38 per share from an option originally granted on 5/10/2022, increasing his directly held common stock to 521,664 shares and leaving 411,245 options outstanding. The filing also reports transactions coded “F” on 01/12/2026 for 17,417 shares at $7.15 and on 01/17/2026 for 22,665 shares at $6.78, after which he directly held 492,079 and then 498,999 common shares. A footnote explains that the option exercise price was paid in cash and that no sales of stock were made. Another footnote states the Form 4 is being reported late due to an inadvertent administrative error.
CorMedix Inc.’s Chief Commercial Officer, Michael David Seckler, reported an equity compensation grant of 133,156 shares of common stock on 01/08/2026. The filing shows these as restricted stock units, each representing the right to receive one share of CorMedix common stock at a stated price of $0 per unit.
The restricted stock units vest over four years in four equal installments on the first four anniversaries of the grant date, and vesting requires Mr. Seckler to remain employed through each applicable vesting date. After this grant, he beneficially owns 133,156 shares directly.
CorMedix Inc. filed an initial ownership report for executive Michael David Seckler, its Chief Commercial Officer, showing no beneficial ownership of company securities. This Form 3 states that no non-derivative or derivative securities are beneficially owned at the time of the report. The filing is signed by an attorney-in-fact under a power of attorney, which authorizes them to sign on the officer’s behalf.
CorMedix Inc. director Steven W. Lefkowitz reported exercising stock options for 15,000 shares of common stock on January 12, 2026. The options had an exercise price of $5.63 per share, and he paid the exercise price in cash. The filing states that no sales of stock were made in connection with this transaction.
After the option exercise, Lefkowitz directly beneficially owns 95,498 shares of CorMedix common stock. He also indirectly beneficially owns 30,152 shares through the Wade Capital Corporation Money Purchase Plan, an entity for which he has voting and investment control, and an additional 2,000 shares are held indirectly through his wife. The exercised option covering 15,000 shares was fully vested and now shows a remaining balance of zero.
CorMedix Inc. filed a current report describing preliminary results and leadership changes. The company issued a press release with preliminary financial results for the quarter and year ended December 31, 2025, noting that the figures are preliminary and subject to completion of audit and accounting procedures.
The report also details an amended and restated employment agreement with CEO Joseph Todisco. His annual base salary increased from $665,000 to $750,000 effective January 1, 2026, and his target annual bonus rose from 65% to 75% of base salary beginning with the 2026 fiscal year. He will continue as Chief Executive Officer and, effective January 8, 2026, will also serve as Chairman of the board of directors. The agreement provides severance protections, including up to 18 months of salary continuation, enhanced benefits and equity acceleration if certain termination or change-in-control conditions occur, and includes confidentiality, non-disparagement, non-compete and non-solicitation covenants.
CorMedix Inc.'s Chief Legal Officer reported an insider share transaction. A Form 4 filing shows a transaction in CorMedix Inc. common stock on January 2, 2026, coded "F". The transaction involved 11,333 shares at a price of $12.16 per share. Following this activity, the reporting person directly beneficially owns 169,085 shares of CorMedix common stock.
CorMedix Inc. director Janet Dillione reported exercising stock options and selling shares of the company’s common stock on 12/09/2025. She exercised options to buy 19,000 shares at $9.55 per share and another 15,000 shares at $5.63 per share, receiving a total of 34,000 shares.
On the same day, she sold 34,000 shares of CorMedix common stock at a weighted average price of $12.00 per share, with individual trades ranging from $12.00 to $12.02. After these transactions, she directly owned 48,473 shares of CorMedix common stock. The exercised options, originally granted in 2016 and 2020 and now fully vested, were reduced to zero following the transactions.
CorMedix Inc. director Steven Lefkowitz reported an open-market sale of common stock. On 12/09/2025, he sold 40,000 shares of CorMedix common stock at a weighted average price of $11.88 per share, with individual trades executed between $11.87 and $11.92. After this transaction, he directly owned 80,498 shares of CorMedix common stock.
In addition to his direct holdings, Lefkowitz is reported to beneficially own 30,152 shares through the Wade Capital Corporation Money Purchase Plan, for which he has voting and investment control, and 2,000 shares held by his wife. The filing reflects a routine insider ownership update rather than a company-level financing or operational event.
CorMedix Inc. (CRMD) director reports stock sale. A company director filed a Form 4 disclosing the sale of 30,000 shares of CorMedix common stock on 11/14/2025 at a weighted average price of $11.42 per share. The trades were executed in multiple transactions at prices ranging from $11.41 to $11.44. After this sale, the director beneficially owns 48,473 shares of CorMedix common stock in direct ownership.